DiscGenics announces FDA regenerative medicine advanced therapy designation granted to IDCT for degenerative disc disease

DiscGenics

26 January 2023 - DiscGenics today announced the US FDA granted regenerative medicine advanced therapy designation to injectable disc cell therapy (IDCT or rebonuputemcel), an injectable, allogeneic discogenic progenitor cell therapy for the treatment of symptomatic lumbar degenerative disc disease.

The regenerative medicine advanced therapy designation is based on positive two year clinical data from DiscGenics's first in human study of injectable disc cell therapy. As previously reported, the study demonstrated the potential of injectable disc cell therapy to safely increase disc volume and provide rapid, durable improvements in low back pain, function, quality of life, and pain medication usage out to two years post-injection in patients with lumbar degenerative disc disease.

Michael Wonder

Posted by:

Michael Wonder